Cornercap Investment Counsel’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Cornercap Investment Counsel’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-94,783	Closed	-$175K	–	698
2023 Q1	$175K	Hold	94,783	–	–	0.03%	511
2022 Q4	$105K	Hold	94,783	–	–	0.02%	534
2022 Q3	$222K	Buy	94,783 +52,718	+125%	+$187K	0.04%	483
2022 Q2	$127K	Buy	+42,065	New	+$205K	0.02%	520

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Cornercap Investment Counsel's JNCE Position: Q2 2023 in Review

Cornercap Investment Counsel sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 94,783 shares — an estimated $175K sold.

Cornercap Investment Counsel first reported a position in JNCE in Q2 2022 and held it in 4 quarters. The position peaked at $222K in Q3 2022. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Cornercap Investment Counsel reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cornercap Investment Counsel sold 94,783 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $175K.
Cornercap Investment Counsel first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Cornercap Investment Counsel's Jounce Therapeutics, Inc. Common Stock position peaked at $222K in Q3 2022.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.